Rationale and design of decision: A double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Brose, Marcia S ^a   Nutting, Christopher M ^b   Sherman, Steven I ^c   Shong, Young K ^d   Smit, Johannes W A ^e   Reike, Gerhard ^f   Chung, John ^g   Kalmus, Joachim ^f   Kappeler, Christian ^f   Schlumberger, Martin ^h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d University of Ulsan College of Medicine   (South Korea)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f BAYER PHARMA AG   (Germany)

^g BAYER CORPORATION   (United States)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RADIOACTIVE IODINE; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SURVIVAL; COLON PERFORATION; CONTROLLED STUDY; DIARRHEA; DIFFERENTIATED THYROID CANCER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; FOLLOW UP; FOOT PAIN; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOCALCEMIA; INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYOPATHY; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TOOTH PAIN; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SURVIVAL; THYROID TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; RESEARCH DESIGN; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 80051479922     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-349     Document Type: Article

References (18)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman, Zhang Y. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009, 20:525-531. 10.1007/s10552-008-9260-4, 2788231, 19016336.
3. Yu GP, Li JC, Branovan D, McCormick S, Schantz SP. Thyroid cancer incidence and survival in the National Cancer Institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 2010, 20:465-473. 10.1089/thy.2008.0281, 20384488.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle DM. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214. 10.1089/thy.2009.0110, 19860577, American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.
5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167. 10.1001/jama.295.18.2164, 16684987.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
7. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655. 10.1097/00000421-198212000-00014, 7165009.
8. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006, National Cancer Institute.
9. Keefe SM, Cohen MA, Brose MS. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 2010, 126:778-783.
10. Brose MS, Troxel AB, Redlinger M, Harlacker K, Redlinger C, Chalian AA, Flaherty KT, Loevner LA, Mandel SJ, O'Dwyer PJ. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients [abstract]. J Clin Oncol 2009, 27:6002.
11. Brose MS, Troxel AB, Harlacker K, Redlinger M, Chalian AA, Loevner LA, Mandel SJ, O'Dwyer PJ, Keefe SM. Completion of a phase II study of sorafenib for advanced thyroid cancer [abstract]. Eur J Cancer Suppl 2009, 7:22. (abstract 51LBA).
12. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719. 10.1200/JCO.2008.16.3279, 2653134, 18541894.
13. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684. 10.1200/JCO.2008.18.2717, 2668972, 19255327.
14. Ahmed M, Barbachano Y, Riddell AM, Whittaker S, Newbold K, Harrington K, Marais R, Nutting CM. Preliminary results of an open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer [abstract]. J Clin Oncol 2008, 26:6060.
15. Ahmed M, Barbachano Y, Riddell AM, Whittaker S, Newbold K, Harrington K, Marais R, Nutting C. An open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer [abstract]. Ann Oncol 2008, 19(Suppl 8):218. (abstract 691PD).
16. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009, 161:923-931. 10.1530/EJE-09-0702, 19773371.
17. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003, 21:3226-3235. 10.1200/JCO.2003.10.130, 12947056.
18. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009, 69:4885-4893. 10.1158/0008-5472.CAN-09-0727, 2690720, 19487299.